Rhythm Pharmaceuticals (RYTM) Receivables - Net (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has reported Receivables - Net for 6 consecutive years, with $34.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Net rose 91.82% year-over-year to $34.2 million; the TTM figure through Mar 2026 stood at $34.2 million (up 91.82% YoY), while the FY2025 annual figure was $26.1 million, up 40.89% from the prior year.
• Receivables - Net grew to $34.2 million in Q1 2026 per RYTM's latest filing, from $26.1 million in the prior quarter.
• Across five years, Receivables - Net topped out at $34.2 million in Q1 2026 and bottomed at $862000.0 in Q1 2022.
• Historically, Receivables - Net has averaged $15.9 million across 5 years, with a median of $14.9 million in 2023.
• Annual changes were most pronounced in 2023 — Receivables - Net soared 841.65% — and 2025, when it grew 21.3%.
• Rhythm Pharmaceuticals' Receivables - Net stood at $6.2 million in 2022, then soared by 138.87% to $14.9 million in 2023, then gained by 24.52% to $18.5 million in 2024, then jumped by 40.89% to $26.1 million in 2025, then jumped by 31.1% to $34.2 million in 2026.
• Business Quant data shows RYTM's Receivables - Net at $34.2 million in Q1 2026, $26.1 million in Q4 2025, and $33.0 million in Q3 2025.